Collegium Pharmaceutical Stock Price and Value Analysis

Collegium Pharmaceutical (NasdaqGS:COLL) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Collegium Pharmaceutical to reach your target.

Target type

COLL Free Cash Flow Trend

Free Cash Flow trendline for COLL
Free Cash Flow trendline for Collegium Pharmaceutical
CSV

Based on historical returns, we believe that Collegium Pharmaceutical can grow its free cash at a rate of about 11%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a great rate!
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company pays no dividend.

Inside the COLL Numbers

COLL Price
(Collegium Pharmaceutical stock price per share)
$25.21
[?] COLL Fair Price
(based on intrinsic value)
$9.71
[?] COLL Safety Price (based on a variable margin of safety) $5.83
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 17% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 75%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Collegium Pharmaceutical's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2025-08-13 Rubric Capital Management LP Sell 25,000 $37.85

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,194,875 shares shorted. With 28,274,907 shares available for purchase and an average trading volume over the past 10 trading days of 655,860, it would take at least 7.9 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2013 1267565 -16.7
2014 1267565 -18.1
2015 1267565 -21.8
2016 1267565 -75.3
2017 1267565 -67.4
2018 1267565 168
2019 1267565 25
2020 1267565 90.2
2021 1267565 99.5
2022 1267565 120
2023 1267565 272
2024 1267565 203
2025 1267565 328

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 5 fiscal years from 2013 to 2025 with positive net income, operating cash flow totaled $1,007 million against net income of $278 million, or 3.61 times. Net income was negative in 8 of the 13 years, and those years are left out of the ratio.

In 2025, capital expenditures were $1.7 million, 0.5% of operating cash flow of $329 million, which leaves an estimated $328 million after capex. Across the 8 years with reported capex, it averaged 1.9% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2013 -16.2 -16.5 0.2 n/a
2014 -17.9 -17.9 0 n/a
2015 -27.3 -21.6 0.4 n/a
2016 -94.2 -75.1 0.5 n/a
2017 -74.9 -67 1 n/a
2018 -39.1 169 5.5 n/a
2019 -22.7 27.8 6.4 n/a
2020 26.8 93.9 5.5 3.51
2021 71.5 104 1.9 1.45
2022 -25 124 1.6 n/a
2023 48.2 275 0.5 5.71
2024 69.2 205 1.7 2.96
2025 62.9 329 1.7 5.24

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 5 fiscal years from 2021 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $1,022 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 5 of the 5 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $222 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $25.1 million, 7.7% of estimated free cash flow of $328 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2021 99.5 n/a 47.9 47.9 48.1%
2022 120 n/a 14.1 14.1 11.7%
2023 272 n/a 75 75 27.6%
2024 203 n/a 60 60 29.6%
2025 328 n/a 25.1 25.1 7.7%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1.7 million in 2016 and $781 million in 2025, a compound annual growth rate of 97.5% over 9 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 23.6% from 2024 to 2025.

Our estimated free cash flow was $328 million in 2025, 42.0% of revenue. In 2016 the estimated margin was negative 4401.9%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 1.7 -75.3 -4401.9%
2017 28.5 -67.4 -236.8%
2018 280 168 59.9%
2019 297 25 8.4%
2020 310 90.2 29.1%
2021 277 99.5 35.9%
2022 464 120 25.9%
2023 567 272 47.9%
2024 631 203 32.1%
2025 781 328 42.0%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $231 million against total liabilities of $1,355 million, or 17.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 81.8% of total assets in 2025, compared with 1855.4% in 2014, a decrease of 1773.6 percentage points.

Stockholders equity was $302 million in 2025, up from negative equity of -$89.3 million in 2014.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 33.3% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2014 5.1 1.6 94.4 -89.3
2015 97.7 95.7 12.6 85.1
2016 162 153 27.1 135
2017 136 119 31.5 104
2018 291 147 200 91.6
2019 306 170 219 87.4
2020 644 174 458 186
2021 692 186 489 203
2022 1,174 174 979 195
2023 1,143 239 948 195
2024 1,664 70.6 1,435 229
2025 1,657 231 1,355 302

Price Versus Our Estimated Value

Collegium Pharmaceutical reported positive free cash flow in 8 of the 13 fiscal years we have from its current SEC filer.

At $25.21, the price is above our fair value estimate of $9.71 for Collegium Pharmaceutical.

Free cash flow is volatile from year to year, with a variability measure of 75%.

Dividends are not in our data for Collegium Pharmaceutical.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 17% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Collegium Pharmaceutical, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Collegium Pharmaceutical (COLL) 783 23.1 - - 160% above
Amphastar Pharmaceuticals (AMPH) 1,199 12.9 - 0.8% 97% above
Innoviva (INVA) 1,309 7.8 - - 12% above
SIGA Technologies (SIGA) 190 265.0 - 7.1% 86% below
Phibro Animal Health Corporation (PAHC) 1,384 13.6 1.3% - 87% above
LifeVantage Corporation (LFVN) 62 23.3 4.0% - 85% above
ANI Pharmaceuticals (ANIP) 1,571 14.0 - - 190% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1267565.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 5 of the 13 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-19
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: COLL annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in COLL

Does Collegium Pharmaceutical have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: COLL

This example shows how we apply the Trendshare checklist to COLL: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 25.21
    • Market cap: $783M
    • EPS: 1.09
  2. Step 2 — Valuation checks

    • P/E: 23.128
    • FCF yield: —
    • Date checked: Nov 19, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.